At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 208 enrolled
Drug / intervention
GSK1349572 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
In Brief
A Phase 2 clinical trial evaluating GSK1349572 and efavirenz for Infection, Human Immunodeficiency Virus. Completed, enrolled 208 participants across 35 sites in 6 countries.
Detailed Summary
This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection, Human Immunodeficiency Virus
CountriesFrance, Germany, Italy, Russia, Spain, United States
CollaboratorsShionogi, GlaxoSmithKline
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedAug 2009
Primary CompletionFeb 2010
Study CompletionDec 2016
TodayJul 2026
First PostedAug 3, 2009
Enrollment StartJul 30, 2009
Primary CompletionFeb 26, 2010
Study CompletionDec 22, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.9 years ago
Interventions
GSK1349572drug
investigational HIV-1 integrase inhibitor
efavirenzdrug
approved therapy for HIV-1 infection, used as an internal study control